/

Società

Ad

Non verificato

AdvanCell

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

16 comunicati stampa

Guarda tutti i comunicati

23/10/2026

Scienza

Biotecnologia

Farmaceutica

Oncologia

Salute

Medicina - Varie

Eventi

Fiere

Industria

AdvanCell Presents Updated Phase 1 Results on ADVC001 at ESMO 2026 with Encouraging Long-term Data

Fonte

Emittente

1.00

0

15/09/2026

AdvanCell Appoints Sean Cassidy as Chief Financial Officer

Fonte

Emittente

1.00

0

21/07/2026

Eventi

Fiere

Scienza

Medicina nucleare

Biotecnologia

Farmaceutica

Oncologia

Salute

Medicina - Varie

AdvanCell to Present Updated Phase 1b Results from the TheraPb Trial at ESMO Congress 2026

Fonte

Emittente

1.00

0

15/07/2026

Scienza

Medicina nucleare

Hardware informatico

Farmaceutica

Information Technology

Oncologia

Tecnica

Attrezzature medico-sanitarie

Medicina - Varie

Biotecnologia

Igiene alimentare

Salute

AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructure

Fonte

Emittente

1.00

0

22/06/2026

Oncologia

Salute

Medicina - Varie

Medicina nucleare

Farmaceutica

Biotecnologia

AdvanCell Establishes U.S. Global Headquarters and Secures Flagship Manufacturing Facility in Greater Boston to Drive Growth Strategy

Fonte

Emittente

1.00

0

08/06/2026

Mercato del lavoro

Biotecnologia

Salute

Medicina nucleare

Farmaceutica

Oncologia

Scienza

Vetrine/Shopping

Medicina - Varie

AdvanCell Strengthens Executive Leadership to Accelerate U.S. Expansion and Scale its Global Targeted Alpha Therapy Platform

Fonte

Emittente

1.00

0

24/02/2026

Eventi

Industria

Scienza

Medicina - Varie

Biotecnologia

Medicina nucleare

Farmaceutica

Vetrine/Shopping

Salute

Oncologia

AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 2026

Fonte

Emittente

1.00

0

02/02/2026

Mercato del lavoro

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need

Fonte

Emittente

1.00

0

08/12/2025

Industria

Terza età

Medicina - Varie

Biotecnologia

Medicina nucleare

Salute

Vetrine/Shopping

Farmaceutica

Oncologia

AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies

Fonte

Emittente

1.00

0

02/12/2025

Eventi

Industria

Oncologia

Salute

Igiene alimentare

Medicina nucleare

Medicina - Varie

Farmaceutica

Biotecnologia

AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0